Unapproved prescription cough, cold, and allergy drug products: Recent US Food and Drug Administration regulatory action on unapproved cough, cold, and allergy medications

Chest

Volumn 140, Issue 2, 2011, Pages 295-300

  Ostroff, Craig ^a,b   Lee, Charles E ^b   McMeekin, Judith ^b  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTICOLD AGENT; ANTITUSSIVE AGENT; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG;

ALLERGY; COLD; COUGHING; DRUG APPROVAL; DRUG CONTROL; DRUG EFFICACY; DRUG FORMULATION; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; MEDICATION ERROR; NOTE; PRESCRIPTION; PRIORITY JOURNAL; STANDARDIZATION;

EID: 80051479222     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-0981     Document Type: Note

References (26)

1. Drugs@FDA. US Food and Drug Administration Web site. http://www. accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed April 11, 2011.
2. OTC human drugs that are generally recognized as safe and effective and not misbranded. 21 CFR §§330-358 (2010).
3. Federal Food, Drug, and Cosmetic Act, Sect 201(p), Chap II - Definitions, 21 USC §321 (2011).
4. Federal Food, Drug, and Cosmetic Act, Sect 505, New Drugs, 21 USC §355 (2011).
5. Adequate and well-controlled studies. 21 CFR §314.126 (2010).
6. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for FDA staff and industry marketed unapproved drugs - compliance policy guide: Sec. 440.100 marketed new drugs without approved NDAs or ANDAs. US Food and Drug Administration Web site. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070290.pdf. June 2006. Accessed April 11, 2011.
7. Secretary of Agriculture. Deaths due to elixir of sulfanilamide- Massengill. JAMA. 1937;109(24):1985-1988.
8. Taussig HB. Thalidomide and phocomelia. Pediatrics. 1962;30(4):654-659.
9. Arrowsmith JB, Faich GA, Tomita DK, Kuritsky JN, Rosa FW. Morbidity and mortality among low birth weight infants exposed to an intravenous vitamin E product, E-Ferol. Pediatrics.1989;83(2):244-249. (Pubitemid 19048692)
10. Certain drugs accorded new drug status through rulemaking procedures. 21 CFR §310.502(a)(14) (2010).
11. Drugs for human use; unapproved and misbranded oral drugs labeled for prescription use and offered for relief of symptoms of cold, cough, or allergy; enforcement action dates. Fed Regist. 2011;76(42):11794-11798. Codified at 21 CFR § 310.502.
12. US Food and Drug Administration. Unapproved prescription cough, cold, and allergy products. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/ EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/ ucm245106.htm. Published April 1, 2011. Accessed April 11, 2011.
13. Federal Food, Drug, and Cosmetic Act, Sec 503(b)(1)(A), Exemptions and Consideration for Certain Drugs, Devices, and Biological Products, Chap V - Drugs and Devices, 21 USC §353 (2011).
14. Prescription drugs for human use. 21 CFR §201.100(c)(2).
15. Adequate directions for use. 21 CFR §201.5 (2010).
16. Federal Food, Drug, and Cosmetic Act, Sec 503(b)(4)(B), Exemptions and Consideration for Certain Drugs, Devices, and Biological Products, Chap V - Drugs and Devices, 21 USC §353 (2011).
17. Cold, cough, allergy, bronchodilator and asthmatic drug products for over-the-counter human use. 21 CFR §341 (2010).
18. Federal Food, Drug, and Cosmetic Act, Sec 502(f)(1), Misbranded Drugs and Devices, Chap V - Drugs and Devices, 21 USC §352 (2011).
19. US Food and Drug Administration. Public health advisory: FDA recommends that over-the-counter (OTC) cough and cold products not be used for infants and children under 2 years of age. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051137. htm. Published February 23, 2011. Accessed April 11, 2011.
20. Chang AB, Glomb WB. Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(suppl 1):260S-283S. (Pubitemid 43265230)
21. Testimony of David Bromberg, MD, FAAP, on behalf of the American Academy of Pediatrics before the Joint Meeting of the Food and Drug Administration Nonprescription Drugs Advisory Committee and Pediatric Advisory Committee, Silver Spring, Maryland, October 19, 2007. US Food and Drug Administration Web site. http://www.fda.gov/ohrms/dockets/ac/07/transcripts/2007-4323t2-Part3.pdf. Accessed April 11, 2011.
22. American Academy of Pediatrics, Committee on Drugs. Use of codeine- and dextromethorphan-containing cough remedies in children. Pediatrics. 1997;99(6):918-920.
23. Pratter MR. Cough and the common cold: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(suppl 1):72S-74S. (Pubitemid 43265207)
24. US Food and Drug Administration. Orange book: approved drug products with therapeutic equivalence evaluations. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Updated December 21, 2010. Accessed April 30, 2011.
25. US Food and Drug Administration. National drug code directory. US Food and Drug Administration Web site. http://www.accessdata.fda.gov/scripts/cder/ ndc-old/default.cfm. Updated June 1, 2011. Accessed June 1, 2011.
26. US Food and Drug Administration. MedWatch online voluntary reporting form (3500). US Food and Drug Administration Web site. https://www.accessdata.fda. gov/scripts/medwatch/medwatch-online.htm. Published April 1, 2011. Accessed April 11, 2011.